Can You Have Both PMDD and Major Depressive Disorder?

You can absolutely have both PMDD and major depressive disorder at the same time, and the combination is more common than many clinicians realize. A systematic review found that the association between the two conditions ranges enormously across studies, but the direction is consistent: having PMDD raises the likelihood of depression, and having a history of depression raises the odds of PMDD.¹ The tricky part is not whether both can coexist but how to tell them apart well enough to treat each one properly.

Why the Two Conditions Are So Easy to Confuse

PMDD and major depressive disorder (MDD) share some of the same core symptoms: low mood, irritability, difficulty concentrating, fatigue, and changes in sleep or appetite. During the late luteal phase, someone with PMDD can look clinically identical to someone in a depressive episode. The key difference is timing. PMDD symptoms appear roughly seven to ten days before menstruation begins and fade within a few days of the start of bleeding.² MDD, by contrast, persists regardless of where you are in your cycle. If your depression lifts reliably after your period starts, that pattern points toward PMDD. If it never fully lifts, you may be dealing with MDD, or both.

There is also a third possibility that complicates things further: premenstrual exacerbation (PME) of an existing mood disorder. This is when someone already has ongoing depression or bipolar disorder, and their symptoms get noticeably worse premenstrually. Studies estimate that roughly 60% of women with mood disorders experience this kind of premenstrual worsening.³ PME is not the same as having both PMDD and MDD. In PME, the underlying depression is always there at some level; it just flares before your period. In true comorbidity, you have a standalone PMDD that would exist even without MDD, plus a separate depressive disorder on top of it. Researchers have noted that the lack of clear differentiation between PME and PMDD-plus-MDD comorbidity is one of the biggest gaps in the existing literature.³

How Prospective Tracking Changes the Picture

The DSM-5 requires that PMDD symptoms be confirmed by daily ratings recorded for at least two consecutive symptomatic cycles.² This is not just a formality. When people track their moods daily against their cycle, the pattern that emerges often looks different from what they remembered. Someone who thinks their depression is constant may discover it has a clear premenstrual spike, suggesting PME. Someone who assumed everything was hormonal may find that low mood persists well into the follicular phase, pointing toward underlying MDD.

For people who suspect they have both conditions, two months of daily tracking is the single most useful diagnostic step. You are looking for two distinct patterns layered on top of each other: a baseline level of depressive symptoms that never fully clears, plus a pronounced worsening in the week or so before your period that goes beyond your usual depression. If both patterns show up consistently across cycles, that is strong evidence for comorbidity. If the premenstrual spike is the only pattern, that favors standalone PMDD. If your symptoms are flat across the entire cycle with no premenstrual spike, PMDD is unlikely even if the symptoms are severe.

Different Biology Under the Hood

One reason both conditions can coexist is that they appear to involve partially different biological mechanisms. The leading theory behind PMDD centers on abnormal sensitivity to a neurosteroid called allopregnanolone, which fluctuates naturally across the menstrual cycle. Allopregnanolone normally modulates a key calming system in the brain. In people with PMDD, the brain’s response to those fluctuations goes awry, leading to the sudden onset of mood and behavioral symptoms in the luteal phase.⁴⁵

MDD, on the other hand, involves broader disruptions in serotonin, norepinephrine, and stress-response pathways that are not tied to a particular phase of the menstrual cycle. Research comparing women with PMDD, women with a history of MDD, and women with both has found genuinely distinct physiological signatures. Women with PMDD showed blunted sympathetic nervous system responses to stress compared to those without PMDD, regardless of whether they also had depression. Meanwhile, women with a history of MDD showed exaggerated blood pressure responses to stress, regardless of whether they had PMDD. Only in women who had both conditions did certain patterns emerge that were absent in either condition alone, such as lower cortisol levels in PMDD women who also had MDD histories.⁶ The takeaway is that PMDD and MDD produce overlapping symptoms through partially independent biological routes, which is exactly why you can have both.

The Brain Connectivity Angle

Brain imaging research adds another layer. A study using resting-state functional MRI found that women with PMDD showed altered connectivity in brain networks involved in attention and executive control compared to healthy controls, and that this difference persisted across the menstrual cycle rather than only appearing in the luteal phase.⁷ The same study also found that the way the amygdala connected to other brain regions shifted between menstrual phases in healthy women, but this shift was smaller in women with PMDD.⁸ These findings suggest that PMDD involves trait-level differences in how the brain is wired, not just state-level changes that come and go with hormones. MDD has its own well-documented connectivity abnormalities, particularly involving the default mode network and prefrontal cortex. Two sets of connectivity problems, running partly on different circuits, can coexist in the same brain.

Shared Genetic Roots

Genetic studies suggest PMDD is heritable, though specific genes have not been pinned down.⁹ What has become clearer is that the genetic risk for premenstrual disorders overlaps with the genetic risk for several major psychiatric conditions. A large study using polygenic risk scores found that the genetic liability for major depression was significantly associated with symptoms of premenstrual disorders. The same was true for bipolar disorder and other psychiatric conditions, but not for a control trait like height.¹⁰

This genetic overlap helps explain the high comorbidity rates from a different angle. If the same gene variants that predispose someone to depression also increase vulnerability to PMDD, then developing both is not a coincidence but a reflection of shared underlying biology. It also means that family history of depression is a risk factor worth paying attention to. If depression runs in your family, your risk of PMDD may be higher than average, and vice versa.

How Treatment Changes When You Have Both

SSRIs are a first-line treatment for both PMDD and MDD, but the way they work in each condition appears to be different. In MDD, SSRIs typically take several weeks to reach full effect and need to be taken daily. In PMDD, the response is much faster, and effective doses tend to be lower than what is needed for depression.¹¹ This rapid onset has led researchers to suspect that SSRIs work through a different mechanism in PMDD than in depression, likely acting on allopregnanolone metabolism rather than simply boosting serotonin over weeks of continuous use.¹²

For standalone PMDD, this means a unique dosing option is available: luteal-phase-only dosing, where you take the SSRI only during the roughly two weeks before your period. Research shows that this approach works as well as daily dosing for many people with PMDD.¹³ Some evidence even supports symptom-onset dosing, where you start the SSRI only when premenstrual symptoms appear.¹⁴

When both PMDD and MDD are present, though, intermittent dosing becomes more complicated. If you stop the SSRI after your period starts, the MDD portion of your symptoms has no pharmacological support for the rest of the cycle. Most clinicians treating comorbid PMDD and MDD will prescribe a daily SSRI at a dose sufficient for the depression, sometimes with an increased dose during the luteal phase to address the premenstrual spike. This “luteal dose bump” strategy tries to cover both conditions, though it has not been studied as rigorously as either continuous or intermittent dosing alone.

When Hormonal Treatments Hit a Wall

For PMDD that does not respond adequately to SSRIs, hormonal approaches are another option. These can include certain oral contraceptives or, in severe cases, medications that temporarily shut down ovarian cycling. The logic is straightforward: if PMDD is triggered by the hormonal fluctuations of the menstrual cycle, eliminating those fluctuations should eliminate PMDD symptoms. And for standalone PMDD, this often works. But when MDD is also in the picture, things can go differently.

A pilot study testing a hormone-suppressing medication in women with premenstrual symptoms found that participants who had comorbid depression showed little improvement in either their premenstrual or depressive symptoms, even though their menstrual cycles stopped. Women with premenstrual symptoms alone, by contrast, saw their premenstrual depression scores decrease almost completely.¹⁵ This is a small study, so the findings are preliminary, but the pattern makes intuitive sense. Shutting down hormonal fluctuations removes the trigger for PMDD but does nothing about the separate biological processes driving MDD. If both are present, treating one without addressing the other leaves you only partly better.

The Compounding Effect on Daily Life

Having both conditions together is not just the sum of their parts. Research on quality of life in women with PMDD found that those who also had psychiatric comorbidities scored substantially lower across every domain of well-being compared to those with PMDD alone. The psychological domain showed the largest gap, but physical health, social relationships, and environmental factors all took a measurable hit as well.¹⁶ When depression is constant and then intensifies premenstrually, the cumulative burden on relationships, work, and self-image can be severe. The luteal phase becomes a predictable crisis period layered on top of an already difficult baseline.

The safety implications are also worth understanding. PMDD on its own carries serious suicide risk, with one survey finding that about 30% of people with PMDD had attempted suicide in their lifetime.² When co-existing depression, anxiety, and stress are added to the picture, the risk escalates further. A study of university students found that the association between PMDD and suicidal ideation and attempts was mediated by these co-existing conditions, meaning that the combination of PMDD plus depression or anxiety was driving the elevated risk more than either condition alone.¹⁷ If you have both conditions, being connected to mental health care is especially important during the premenstrual phase.

PMDD as a Predictor Across Reproductive Transitions

The relationship between PMDD and depression extends beyond the menstrual years. Research has found that moderate to severe premenstrual symptoms nearly doubled a woman’s chances of developing postpartum depression, independent of other risk factors.¹⁸ The connection continues into the menopausal transition as well. A study of postmenopausal women with bipolar disorder found that a history of premenstrual symptoms was associated with a six-fold increase in the odds of experiencing any mood episode during perimenopause, and roughly a two-and-a-half-fold increase in the odds of perimenopausal depression specifically.¹⁹

These findings suggest that PMDD may be a marker of broader vulnerability to hormonally triggered mood disruption across the lifespan. If your brain reacts strongly to the hormonal shifts of the menstrual cycle, it may also react strongly to the hormonal upheaval of pregnancy, the postpartum period, and perimenopause. For someone who already has MDD, this means that every major reproductive transition is a period of heightened risk that deserves proactive planning with a clinician.

An Evolutionary Footnote

One of the more unusual threads in the PMDD literature is the question of whether premenstrual symptoms could have had an evolutionary advantage. A hypothesis published in an evolutionary biology journal proposed that PMS-related behaviors, particularly the hostility and irritability directed at a current partner, could have increased the likelihood that infertile pairings would dissolve, freeing the woman to find a new partner with better reproductive prospects.²⁰ The authors pointed to PMS’s high heritability and the observation that premenstrual hostility tends to be aimed preferentially at current romantic partners as circumstantial support for the idea. This remains speculative, and it applies to PMS broadly rather than to the clinical severity of PMDD specifically. It also says nothing about MDD, which has its own separate evolutionary literature. But the hypothesis does underline one practical point: the irritability and interpersonal friction of PMDD are not personal failures. They appear to be deeply wired responses to hormonal signals, ones that can be managed medically rather than endured through willpower alone.

Bright Light Therapy and Adjunctive Approaches

Given that both PMDD and MDD involve mood disruption, people sometimes ask whether adjunctive interventions like bright light therapy might help. Light therapy has reasonable evidence behind it for seasonal depression and some forms of MDD. For PMDD-associated depression, the evidence is thinner. A pooled analysis of higher-quality crossover trials studying bright light therapy for PMDD-related depression found a small effect that did not reach statistical significance.²¹ The studies were small, with only about 55 participants total across the included trials, so light therapy cannot be ruled out entirely, but it is not a well-supported standalone treatment for PMDD at this point. For someone with both PMDD and MDD, light therapy might offer marginal benefit for the depressive component, but it should not replace SSRI treatment or other first-line approaches for either condition.

Exercise, stress management, and sleep hygiene are commonly recommended as complementary strategies for both conditions. None of these are substitutes for medication in moderate-to-severe cases, but they can reduce the overall symptom load. For someone managing two overlapping mood disorders, even modest reductions in baseline stress or improvements in sleep quality can make the premenstrual phase more survivable.

1
Journal of Affective Disorders Reports. The association between premenstrual dysphoric disorder and depression: A systematic review
2
JMIR Publications. Developing a Mood and Menstrual Tracking App for People With Premenstrual Dysphoric Disorder: User-Centered Design Study
3
Europe PMC. Premenstrual Exacerbations of Mood Disorders: Findings and Knowledge Gaps
4
PubMed Central. Role of allopregnanolone-mediated γ-aminobutyric acid A receptor sensitivity in the pathogenesis of premenstrual dysphoric disorder: Toward precise targets for translational medicine and drug development
5
Neurobiology of Stress. Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle
6
PubMed Central. Histories of major depression and premenstrual dysphoric disorder: Evidence for phenotypic differences
7
PubMed Central. Resting-state functional connectivity in women with PMDD
8
Translational Psychiatry. Resting-state functional connectivity in women with PMDD
9
PubMed Central. Towards understanding the biology of premenstrual dysphoric disorder: From genes to GABA
10
JAMA Psychiatry. Associations Between Symptoms of Premenstrual Disorders and Polygenic Liability for Major Psychiatric Disorders
11
Psychopharmacology Institute. Psychopharmacology for PMS and PMDD: Luteal Phase Dosing and Choosing Among SSRIs
12
PubMed. Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard?
13
PubMed. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder
14
PubMed. Luteal phase and symptom-onset dosing of SSRIs/SNRIs in the treatment of premenstrual dysphoria: clinical evidence and rationale
15
PubMed. Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study
16
Journal of Contemporary Clinical Practice. Psychiatric Comorbidity and Quality of Life in Women with Premenstrual Dysphoric Disorder
17
PubMed Central. Premenstrual dysphoric disorder and its co-existence with depression, anxiety, and stress as risk factors for suicidal ideation and suicide attempts among university students in Bangladesh: A single-site survey
18
PubMed Central. Examination of premenstrual symptoms as a risk factor for depression in postpartum women
19
PubMed Central. Associations between lifetime reproductive events among postmenopausal women with bipolar disorder
20
PubMed Central. Were there evolutionary advantages to premenstrual syndrome?
21
PubMed. The effect of bright light therapy on depression associated with premenstrual dysphoric disorder